Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic multispecific antiviral T cells
- Development stage
- Unknown
- Lead developer
- University Hospital Freiburg
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Allogeneic multispecific antiviral T cells is an investigational adoptive cell therapy consisting of allogeneic CD4+ and CD8+ T lymphocytes that have been ex vivo stimulated with synthetic peptides derived from the viral antigens of cytomegalovirus (CMV), Epstein-Barr virus (EBV), and adenovirus (AdV). Developed by the Medical Center – University of Freiburg, the therapy is intended to restore virus-specific immunity in patients following allogeneic hematopoietic stem cell transplantation (HSCT) who suffer from chemotherapy-refractory viral infections. The product is currently being evaluated in the Phase III TRACE multicenter clinical trial, building on earlier Phase I/IIa results from the MULTIVIR-01 study.
- Other names
- multispecific antiviral T cellsallogeneic multispecific CD4+ and CD8+ T cells
02
Targets
pp65/HLA-A*02:01 (CMV pp65 peptide-HLA-A*02:01 complex)pMHC (Peptide-MHC complex family)HAdV (Human adenovirus)
Beyond the preview
Go deeper on allogeneic multispecific antiviral T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic multispecific antiviral T cells.